1. Virtual Alanine Scan of the Main Protease Active Site in Severe Acute Respiratory Syndrome Coronavirus 2
- Author
-
Akifumi Oda, Koichi Kato, Tomoki Nakayoshi, and Eiji Kurimoto
- Subjects
QH301-705.5 ,medicine.medical_treatment ,Mutant ,Mutation, Missense ,Drug resistance ,Article ,Catalysis ,Inorganic Chemistry ,Residue (chemistry) ,Catalytic Domain ,medicine ,Humans ,Biology (General) ,Physical and Theoretical Chemistry ,QD1-999 ,Molecular Biology ,Coronavirus 3C Proteases ,Spectroscopy ,Alanine ,chemistry.chemical_classification ,Protease ,drug resistance ,biology ,SARS-CoV-2 ,Chemistry ,Organic Chemistry ,Active site ,COVID-19 ,General Medicine ,Ligand (biochemistry) ,Computer Science Applications ,Amino acid ,molecular dynamics simulation ,Amino Acid Substitution ,Biochemistry ,main protease ,virtual alanine scan ,biology.protein ,severe acute respiratory syndrome coronavirus 2 - Abstract
Recently, inhibitors of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) have been proposed as potential therapeutic agents for COVID-19. Studying effects of amino acid mutations in the conformation of drug targets is necessary for anticipating drug resistance. In this study, with the structure of the SARS-CoV-2 Mpro complexed with a non-covalent inhibitor, we performed molecular dynamics (MD) simulations to determine the conformation of the complex when single amino acid residue in the active site is mutated. As a model of amino acid mutation, we constructed mutant proteins with one residue in the active site mutated to alanine. This method is called virtual alanine scan. The results of the MD simulations showed that the conformation and configuration of the ligand was changed for mutants H163A and E166A, although the structure of the whole protein and of the catalytic dyad did not change significantly, suggesting that mutations in His163 and Glu166 may be linked to drug resistance.
- Published
- 2021
- Full Text
- View/download PDF